Sai Life Sciences is a contract manufacturer based in India. It holds 8 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by CDSCO (India) and US FDA. Its most recent recorded inspection, by US FDA, closed on 14 June 2024 as VAI. Customs aggregates show $44.7M of exports covering 1,901 molecules to 20 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | 3004602077 |
| bidar 585 403, India | Not on file |
| Bidar, India | Not on file |
| Bidar, India | 3006398900 |
| Hyderabad, India | 3005301950 |
| Molecule | Regulators | Docs |
|---|---|---|
| Dapsone | US FDA | 2 |
| Doxercalciferol | US FDA | 2 |
| Ibutilide | US FDA | 2 |
| Paricalcitol | US FDA | 2 |
| Bilastine | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | None | 2 |
| US FDA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $23.1M | 18 |
| 2025 | Not reported | $44.7M | 20 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Sai Life Sciences comes back tiered against every other supplier able to file there.
Start for free